In 2004, the Securities and Exchange Commission and the Food and Drug Administration announced steps to enhance cooperation between them to further protect the public from false and misleading statements by public life sciences companies. The agencies developed a centralized process where the FDA could refer potential disclosure matters to the SEC’s Division of Enforcement, and identify FDA point persons and procedures for the SEC to use when gathering information about public life-sciences companies. Reprinted with permission from Portfolio Media, Inc.
Related Insights
May 22, 2026
Foley Viewpoints
New Lawsuit Tests the Limits of Donor-Advised Fund Advisory Privileges
A recent lawsuit seeking to clarify the extent of an advisor’s privileges with respect to a donor-advised fund (DAF) has been filed in…
May 22, 2026
Energy Current
FERC Just Rewrote the Rules for Natural Gas Infrastructure. Here’s What It Means.
Yesterday’s unanimous FERC vote is the most significant natural gas permitting reform in two decades — and its practical implications…
May 22, 2026
Foley Viewpoints
What the Federal Circuit’s Poultry Patent Ruling Says About 'About'
The decision does not appear to prohibit the use of terms such as "about" or "approximately." Rather, it reinforces that such terms may be acceptable where the patent record provides sufficient context for understanding the scope of the claimed range.